Boston Trust Walden Corp Has $120.48 Million Position in Chemed Corporation $CHE

Boston Trust Walden Corp increased its stake in shares of Chemed Corporation (NYSE:CHE) by 0.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 247,434 shares of the company’s stock after buying an additional 1,083 shares during the quarter. Chemed comprises approximately 0.9% of Boston Trust Walden Corp’s investment portfolio, making the stock its 25th biggest position. Boston Trust Walden Corp owned about 1.69% of Chemed worth $120,483,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in CHE. Fuller & Thaler Asset Management Inc. grew its position in Chemed by 249.3% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 130,037 shares of the company’s stock worth $80,015,000 after buying an additional 92,813 shares in the last quarter. Woodline Partners LP grew its position in Chemed by 2,681.0% during the first quarter. Woodline Partners LP now owns 58,178 shares of the company’s stock worth $35,798,000 after buying an additional 56,086 shares in the last quarter. Nuveen LLC acquired a new stake in Chemed during the first quarter worth approximately $30,527,000. Jacobs Levy Equity Management Inc. acquired a new stake in Chemed during the first quarter worth approximately $26,059,000. Finally, Candriam S.C.A. grew its position in Chemed by 207.7% during the first quarter. Candriam S.C.A. now owns 45,178 shares of the company’s stock worth $27,799,000 after buying an additional 30,495 shares in the last quarter. Institutional investors and hedge funds own 95.85% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on CHE shares. Oppenheimer reduced their target price on Chemed from $650.00 to $580.00 and set an “outperform” rating on the stock in a report on Thursday, July 31st. Royal Bank Of Canada reduced their target price on Chemed from $640.00 to $589.00 and set an “outperform” rating on the stock in a report on Thursday, July 31st. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Chemed in a report on Wednesday, October 8th. Wall Street Zen downgraded Chemed from a “buy” rating to a “hold” rating in a report on Saturday, July 5th. Finally, Bank of America reduced their target price on Chemed from $610.00 to $595.00 and set a “buy” rating on the stock in a report on Wednesday, September 10th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $578.50.

Chemed Stock Down 0.2%

NYSE CHE opened at $429.20 on Tuesday. Chemed Corporation has a twelve month low of $408.42 and a twelve month high of $623.60. The company has a market cap of $6.25 billion, a price-to-earnings ratio of 22.07, a price-to-earnings-growth ratio of 2.50 and a beta of 0.43. The business’s fifty day moving average is $448.56 and its 200 day moving average is $507.92.

Chemed (NYSE:CHE) last released its quarterly earnings data on Tuesday, July 29th. The company reported $4.27 earnings per share for the quarter, missing the consensus estimate of $6.02 by ($1.75). Chemed had a net margin of 11.56% and a return on equity of 25.83%. The firm had revenue of $618.80 million for the quarter, compared to analyst estimates of $650.60 million. During the same period last year, the business earned $5.47 EPS. The company’s revenue was up 3.8% compared to the same quarter last year. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. On average, research analysts anticipate that Chemed Corporation will post 21.43 earnings per share for the current fiscal year.

Chemed Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, August 29th. Investors of record on Monday, August 11th were issued a dividend of $0.60 per share. This is a positive change from Chemed’s previous quarterly dividend of $0.50. The ex-dividend date of this dividend was Monday, August 11th. This represents a $2.40 annualized dividend and a dividend yield of 0.6%. Chemed’s dividend payout ratio (DPR) is 12.34%.

Insider Transactions at Chemed

In related news, Director Patrick P. Grace sold 150 shares of the firm’s stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $463.39, for a total transaction of $69,508.50. Following the sale, the director owned 3,397 shares of the company’s stock, valued at $1,574,135.83. This trade represents a 4.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director George J. Walsh III acquired 200 shares of the business’s stock in a transaction that occurred on Monday, August 4th. The shares were purchased at an average cost of $417.10 per share, for a total transaction of $83,420.00. Following the acquisition, the director owned 3,523 shares in the company, valued at $1,469,443.30. This represents a 6.02% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders sold 13,162 shares of company stock worth $5,677,511. Insiders own 3.29% of the company’s stock.

Chemed Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.